CABA
Cabaletta BioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
+
Peers tracked
9
U.S. public peers
Grade Position
Below peers
vs peer average
CABA vs peer average
34/100
CABA vs. peer average (D vs. C)
Grade spread
A 1 · B 1 · C 5 · D 1 · F 1
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
KYTX is the first available peer comparator.
Kyverna is the most relevant public operating peer: it is also advancing an autologous CD19 CAR-T for autoimmune disease, with registrational work in myasthenia gravis and ongoing lupus nephritis studies, so it is a better read-through for autoimmune CAR-T regulatory design and commercial framing than the original generic small-cap biotech comps.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
CABA
Cabaletta Bio
KYTX
Kyverna Therapeutics
Grade
D
C
Momentum
9
18
Value
41
41
Sentiment
73
84
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Mixed
Grade position vs KYTX
CABA / KYTX
Grade Position
Below peers
CABA vs. peer average (D vs. C)
34/100
Momentum
9
KYTXValue
41
CABASentiment
73
KYTXRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs CABA
KYTX is the first peer returned for this comparison set.